These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23116602)

  • 1. Health-related quality of life in chronic myeloid leukemia.
    Trask PC; Cella D; Powell C; Reisman A; Whiteley J; Kelly V
    Leuk Res; 2013 Jan; 37(1):9-13. PubMed ID: 23116602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
    Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
    Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
    Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
    Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia].
    Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Qiu JY; Lu DP; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):347-50. PubMed ID: 12941187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
    Aziz Z; Iqbal J; Akram M; Saeed S
    Cancer; 2007 Mar; 109(6):1138-45. PubMed ID: 17315159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
    Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
    Meng FY; Zheng WY; Liu XL; Xu B; Song LL; Zhang Y; Huang F
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1149-50. PubMed ID: 14625174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
    Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
    Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
    Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
    Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
    Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
    Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.
    Efficace F; Rosti G; Breccia M; Cottone F; Giesinger JM; Stagno F; Iurlo A; Russo Rossi A; Luciano L; Martino B; Galimberti S; Turri D; Bergamaschi M; Tiribelli M; Fava C; Angelucci E; Mandelli F; Baccarani M
    Ann Hematol; 2016 Jan; 95(2):211-9. PubMed ID: 26546359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated and blastic phases of chronic myelogenous leukemia.
    Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):753-74, xii. PubMed ID: 15271404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
    Mesárosová A; Hrivnáková A; Klobusická M; Babusíková O
    Neoplasma; 1995; 42(1):9-14. PubMed ID: 7617076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
    Cortes JE; Talpaz M; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Rios MB; Shan J; Kantarjian HM
    Cancer; 2006 Mar; 106(6):1306-15. PubMed ID: 16463391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
    Krauth MT; Simonitsch I; Aichberger KJ; Mayerhofer M; Sperr WR; Sillaber C; Schneeweiss B; Mann G; Gadner H; Valent P
    Am J Clin Pathol; 2004 Apr; 121(4):473-81. PubMed ID: 15080298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.